Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treatment of newly diagnosed patients with acute promyelocytic leukaemia (PETHEMA LPA 2005): remission induction with ATRA [tretinoin] + idarubicin. Risk-adapted consolidation with ATRA and anthracycline-based chemotherapy (idarubicin/mitoxantrone) with addition of Ara-C [cytarabine] for high-risk patients. Maintenance therapy with ATRA + low dose chemotherapy (methotrexate + mercaptopurine).

X
Trial Profile

Treatment of newly diagnosed patients with acute promyelocytic leukaemia (PETHEMA LPA 2005): remission induction with ATRA [tretinoin] + idarubicin. Risk-adapted consolidation with ATRA and anthracycline-based chemotherapy (idarubicin/mitoxantrone) with addition of Ara-C [cytarabine] for high-risk patients. Maintenance therapy with ATRA + low dose chemotherapy (methotrexate + mercaptopurine).

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cytarabine; Idarubicin; Mitoxantrone; Tretinoin
  • Indications Acute promyelocytic leukaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 28 Oct 2014 Biomarkers information updated
    • 19 Nov 2013 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.
    • 27 Feb 2013 Planned end date changed from 1 Dec 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top